2 Pharmaceutical Stocks Set to Rebound in 2026

Key Points Novo Nordisk could see stronger financial results this year thanks to new launches and label expansions. Merck's clinical progress this year could show that it will expertly overcome a major upcoming patent cliff. 10 stocks we like better than Novo Nordisk › The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and Merck (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There are solid reasons to think the two l ...